CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 146 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00816907
NCT00816907Phase 4Completed
CompareCT.gov

Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study

National Institute of Mental Health (NIMH)·interventional·Posted Jan 5, 2009·Updated Mar 27, 2013

In Brief

A Phase 4 clinical trial evaluating Metformin and Placebo for Schizophrenia. Completed, enrolled 146 participants across 16 sites.

Detailed Summary

This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 5, 2009
Enrollment StartJan 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.5 years ago

Interventions

Metformindrug

500 mg to 1,000 mg taken twice daily for 16 weeks

Placebodrug

1 to 2 placebo capsules taken twice daily for 16 weeks